Javascript must be enabled to continue!
Open Science: Open Source Licences in Scientific Research
View through CrossRef
The use of non-proprietary software licenses - such as the Free Software (FS) and Open Source Software (OSS) license models - is definitely on the increase, showing that the open development models are viable and sometime even commercially successful systems. Amongst these models, one of the most interesting licenses is that offered by so-called copyleft licenses, which are licenses that allow software to be transferred with the insurance that the source code will remain open, with the caveat that anyone who redistributes the software, with or without changes, must pass along the freedom to further copy and change it.
However, software development is not the only area in which this licensing model could apply. The viral nature of copyleft licenses has generated a considerable amount of interest in circles that transcend software development. The idea of sharing materials is not new, and has been made more evident by the chaotic and sometimes anarchic nature of the internet. However, shared materials tend to suffer from the possibility of third parties that use the freely acquired information to turn them into proprietary works. That is why many different organisations are turning to the copyleft model to protect works that are being freely shared online. One such project is the OpenContent License (OPL), a collaborative effort that sets a similar license to the GPL, ensuring that shared works will continue to remain free to subsequent users. A more ambitious project is the Creative Commons, which offers a wide range of licenses applicable to all sorts of creative material. In the area of biotechnology, there have been some suggestions that the copyleft model could be used to protect the public results of the human genome race being placed in the public domain by several researchers, something that has been suggested by a leading member of the Human Genome Consortium, although the idea has never been implemented.
This paper will explore the application of copyleft licenses to other areas of research and development, and will try to explore if these can be successfully adapted to various different areas where creators want to share their works to the public but want to make sure that there will not be any further commercialisation of their creations.
Title: Open Science: Open Source Licences in Scientific Research
Description:
The use of non-proprietary software licenses - such as the Free Software (FS) and Open Source Software (OSS) license models - is definitely on the increase, showing that the open development models are viable and sometime even commercially successful systems.
Amongst these models, one of the most interesting licenses is that offered by so-called copyleft licenses, which are licenses that allow software to be transferred with the insurance that the source code will remain open, with the caveat that anyone who redistributes the software, with or without changes, must pass along the freedom to further copy and change it.
However, software development is not the only area in which this licensing model could apply.
The viral nature of copyleft licenses has generated a considerable amount of interest in circles that transcend software development.
The idea of sharing materials is not new, and has been made more evident by the chaotic and sometimes anarchic nature of the internet.
However, shared materials tend to suffer from the possibility of third parties that use the freely acquired information to turn them into proprietary works.
That is why many different organisations are turning to the copyleft model to protect works that are being freely shared online.
One such project is the OpenContent License (OPL), a collaborative effort that sets a similar license to the GPL, ensuring that shared works will continue to remain free to subsequent users.
A more ambitious project is the Creative Commons, which offers a wide range of licenses applicable to all sorts of creative material.
In the area of biotechnology, there have been some suggestions that the copyleft model could be used to protect the public results of the human genome race being placed in the public domain by several researchers, something that has been suggested by a leading member of the Human Genome Consortium, although the idea has never been implemented.
This paper will explore the application of copyleft licenses to other areas of research and development, and will try to explore if these can be successfully adapted to various different areas where creators want to share their works to the public but want to make sure that there will not be any further commercialisation of their creations.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
15. Licences
15. Licences
In recent times, there has been considerable development with respect to determining how rights in land can be created and the implications of such rights for purchasers of land. L...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Non-Recommended Publishing Lists: Strategies for Detecting Deceitful Journals
Non-Recommended Publishing Lists: Strategies for Detecting Deceitful Journals
Abstract
The rapid growth of open access publishing (OAP) has significantly improved the accessibility and dissemination of scientific knowledge. However, this expansion has also c...
14. Licences
14. Licences
Licences have long occupied something of an amorphous position; they are not admitted to the category of full proprietary rights, but provide an interesting area where the law seek...
Software Asset Management and Cloud Computing
Software Asset Management and Cloud Computing
Gestion du patrimoine logiciel et Cloud Computing
Dans le Cloud, peu de travaux traitent de l’analyse de l’usage réel et dynamique des logiciels consommés afin de d...

